MARIETTA, Ga.--(EON: Enhanced Online News)--Osmotica Pharmaceutical Corp. today announced the appointment of Kenneth Gayron as Vice President and Chief Financial Officer. In his role, Mr. Gayron will serve as a member of the executive leadership team at Osmotica Pharmaceutical. Praveen Tyle, PhD., President and CEO of Osmotica Pharmaceutical, stated, “Ken brings to the company a wealth of experience in key financial, investment banking and accounting areas, which we intend to utilize as we execute on our business strategy.”
“Ken brings to the company a wealth of experience in key financial, investment banking and accounting areas, which we intend to utilize as we execute on our business strategy.”
Ken has more than 20 years of experience in corporate finance, accounting, mergers and acquisitions and investor relations. Prior to joining Osmotica, Ken was Vice President and Treasurer of Sensus, where he was responsible for leading financial planning, treasury, IR and co-managed the accounting and tax group. Prior to becoming a Corporate Financial Officer, Ken was an Investment Banker for 10 years focused on healthcare and technology. As an Executive Director with UBS Investment Bank and CIBC World Markets, Ken completed over 60 transactions where he provided capital raising and advisory services to healthcare and technology clients. Previously, Ken also served as Treasurer of Nuance Communications, a $2 billion healthcare focused technology company, where he helped complete and integrate several acquisitions.
Ken earned his Masters of Business Administration from Cornell University and his Bachelors of Science from Boston College.
About Osmotica Pharmaceutical
Osmotica Pharmaceutical is a global specialty pharmaceutical company with a proven history of developing commercially successful pharmaceutical products. The company uses its proprietary osmotic technology platform and with strategic partners develops and commercializes high quality pharmaceutical products. In addition to the products currently on the market, the company’s pipeline includes numerous ANDA programs and several innovative neurology-based NDA programs.
Osmotica Pharmaceutical and its related companies form an international group of companies with principal operations located in the United States, Argentina and Hungary.
For more information on the Company, please visit Osmotica’s website at www.osmotica.com. This press release is directed to residents of the United States.